Intervention Study of Communication in Oncologist-Patient Encounters
NCT ID: NCT00994578
Last Updated: 2014-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
659 participants
INTERVENTIONAL
2010-11-30
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The specific aims are to:
AIM 1: Develop a web-based intervention that trains patients with advanced cancer to express their emotional concerns to their oncologists and to request emotional support during clinical encounters.
AIM 2: Test whether this intervention can increase patient expression of emotional concerns and requests for emotional support, as well as improve patient affect by decreasing negative emotions.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating a Bidirectional Priming Intervention for Goals-of-care Communication in Oncology
NCT06955468
Improving Communication Between Cancer Patients & Oncologists
NCT02969031
Communication Effectiveness in Cancer Treatment
NCT02197091
Improving Goals of Care Discussion in Advanced Cancer Patients
NCT02374255
Computer Program in Improving Communication Between Doctors and Patients With Stage IV Cancer
NCT00276627
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Biweekly, we will present participating physicians with a list of potentially eligible patients (those with advanced disease) and ask them to identify those who should not be approached about study participation. Reasons to not approach include dementia or inappropriate disease staging. Identified patients will receive a letter from their treating oncologist inviting them to participate in the study about oncologist-patient communication. Patients who do not wish to be contacted about the study may call a toll-free number to opt out. If patients do not respond, a research assistant will contact them by telephone several days prior to their clinic visit, explain the study in detail, and obtain verbal consent to conduct a phone screener and baseline interview. It is necessary to conduct the screener and baseline survey prior to obtaining written consent so that staff may determine eligibility and then initiate study procedures at the upcoming clinic visit, if appropriate.
The baseline survey includes demographic information and several brief scales. Included in these is the Impact of Events Scale (IES) to determine level of distress, as the COPE study is interested in the subset of patients who are experiencing emotional difficulty with their cancer and may be amenable to support in this domain from their provider. The IES is scored from 0-44, with anything over 8 signifying at least mild levels of distress. Patients who score 10 or below will be excluded from the study. After completing the survey measures, arrangements will be made to meet patients in the clinic before their upcoming visit.
The research assistant will meet the patients in clinic, immediately prior to their next visit, and obtain written informed consent. After engaging in the informed consent process, the research assistant will place the audio recorder in the exam room, turn it on before the oncologist enters the room, exit the room, and then turn off the recorder at the end of the visit. S/he will not be present in the exam room during the visit. Subjects will complete a survey immediately after the visit to assess affect and quality of communication. Immediately after the visit, physicians will complete a very brief questionnaire to assess their perception of the subjects' distress and whether s/he talked about their distress.
Once research assistants determine that participating patients have an appointment with the same oncologist within 3 months, they will randomly assign subjects to one of four study arms (Control, CHESS, COPE, or CHESS+COPE), stratified by site and gender. Research assistants, equipped with laptop computers, will then introduce subjects to the intervention. For subjects in the Control arm, research assistants will use the intervention portal to review general Internet search tools (e.g., google). For subjects in the three intervention arms, research assistants will demonstrate the appropriately modified intervention website and ensure subjects' abilities to use it. Subjects will be provided written materials on the use of the website, and instructions will also be sent shortly afterward by email. The research assistant will call subjects within 7-14 days by phone and administer a 1-week follow-up survey to assess affect. This process will be repeated until staff record up to three clinic visits with the patient subject.
Staff will email and call patient subjects between clinic visits to remind them how to access the intervention website and answer technical questions. Also, research assistants will remind participants that a member of the study team will meet with them at their upcoming oncology appointments.
In the last post-visit call with patient subjects, staff will re-administer the IES. Once patients complete 3 audio-recorded visits, post-visits, and one-week follow-up interviews, study participation will be complete.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Internet Only
Patients assigned to the internet only group will enter the initial CHESS portal which will take them to a window displaying a standard web search engine and common cancer information sites. We will monitor their internet usage via logins to the CHESS portal.
No interventions assigned to this group
CHESS
Participants in the CHESS arm will be given access to the University of Wisconsin CHESS website, modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support. The participant's usage of the site will be monitored.
CHESS
Patients randomized to the CHESS intervention will be trained to access the website. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support
COPE
Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each visit, and access to the patient's audio-recorded conversations for review. The participant's usage of the site will be monitored.
COPE
Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each of two oncologists visits over a maximum of a 9 month period, and access to the patient's audio-recorded conversations for review.
CHESS/COPE
Participants in the CHESS+COPE arm will receive training in, and access to, both components on the CHESS website, with the accompanying levels of support. The participant's usage of the site will be monitored.
CHESS/COPE
Participants in the CHESS/COPE arm will be given access to the University of Wisconsin CHESS modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired and receive technical support. COPE arm will receive training and access to the COPE patient intervention an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to two oncologists visits over a maximum period of 9 months, and access to the patient's audio-recorded conversations for review.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CHESS
Patients randomized to the CHESS intervention will be trained to access the website. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support
COPE
Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each of two oncologists visits over a maximum of a 9 month period, and access to the patient's audio-recorded conversations for review.
CHESS/COPE
Participants in the CHESS/COPE arm will be given access to the University of Wisconsin CHESS modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired and receive technical support. COPE arm will receive training and access to the COPE patient intervention an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to two oncologists visits over a maximum period of 9 months, and access to the patient's audio-recorded conversations for review.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. have a diagnosis of advanced cancer (Stage IV or however defined for that disease group), metastatic disease, or refractory or recurrent illness;
3. have access to a telephone; and,
4. have regular access to a computer with broadband Internet service and an email account.
Exclusion Criteria
2. hearing impaired or have a speech disorder;
3. physically impaired in such a way that precludes the use of a computer;
4. simply too sick to participate, and cannot realistically participate in the interview, as judged by the research assistant; or
5. does not have another appointment with an enrolled oncologist within three months.
6. has dial-up Internet service, or
7. does not meet IES Score.
While only patient subjects with advanced cancer will be eligible for randomization into one of the study arms, healthy volunteers (providers and third parties) will be enrolled in the study, too. Patients will be recruited from the practices of participating oncologists; therefore, physicians will be enrolled prior to their patients. All medical, surgical and radiation oncology faculty and hematology/oncology fellows who see patients in the participating clinics will be eligible for the study. We also will enroll the mid-level providers (i.e., physician assistants and nurse practitioners) who work with many of these oncologists and any third party (friends, family members) who comes to clinic with the enrolled patient.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Duke University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James A Tulsky, MD
Role: PRINCIPAL_INVESTIGATOR
Duke University
Yael Schenker, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburgh
Kathryn Pollak, PhD
Role: STUDY_DIRECTOR
Duke Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Duke University Health System
Durham, North Carolina, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00013032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.